ClinicalTrials.gg
Not yet recruitingNCT07507929Updated Apr 2, 2026

Probiotic for Weight Management in Overweight and Obese Adults

An interventional study of Probiotic and Placebo in Obesity, sponsored by Wecare Probiotics Co., Ltd.. Not yet recruiting at 1 site in China. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-04-02.

Sponsored by Wecare Probiotics Co., Ltd. · Not applicable, Interventional, and Treatment

Phase
Not applicable
Study type
Interventional
Enrollment
76
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Study summary

To evaluate the impact of pasteurized Akkermansia muciniphila Akk11 capsules versus placebo on body composition (including body weight, BMI, body fat percentage, waist-to-hip ratio, wrist circumference, visceral fat area, and basal metabolic rate) and serum lipid parameters (TC, LDL-C, HDL-C, and TG) in overweight and obese adults.

02

Conditions studied

  • Obesity

Browse trials for

03

In context

Obesity

11,522 studies on the registry are indexed under Obesity; 2,033 are open to participants now.

This study's planned enrollment of 76 is above the median of 67 across 9,006 interventional studies indexed under Obesity.

Browse Obesity studies →

Lead sponsor

Wecare Probiotics Co., Ltd. is the lead sponsor of 67 studies on the registry; 23 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. (BMI) ≥ 24 kg/m²;
  2. Able and willing to provide written ;
  3. Willing to comply with the study protocol and required restrictions, including adherence to a low-carbohydrate, energy-restricted diet;
  4. No intention to conceive from 14 days prior to screening until 6 months after study completion, and agreement to use effective during this period

Exclusion criteria

Exclusion Criteria:

  1. Recent use of products with similar functions to the product that may interfere with study outcomes;
  2. History of psychiatric or neurological disorders, celiac disease, lactose intolerance, or known allergies;
  3. Pregnant or breastfeeding women, or those planning to become pregnant during the study period;
  4. Diagnosis of irritable bowel syndrome (IBS), ulcerative colitis, liver cirrhosis, or diabetes mellitus;
  5. Use of antibiotics within 3 months prior to screening;
  6. Inability to comply with the study protocol, including failure to take the investigational product as required or attend scheduled follow-up visits;
  7. Smoking more than 10 cigarettes per day;
  8. Any other condition that, in the opinion of the investigator, would make the participant unsuitable for the study.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
76 participants (estimated)

Study arms

  • Experimental
    Probiotic group

    Pasteurized Akkermansia muciniphila Akk11 capsule, 34 billion TFU/day

    Dietary Supplement: Probiotic

  • Placebo comparator
    Placebo group

    Placebo capsule, one capsules/day

    Dietary Supplement: Placebo

Interventions

  • Dietary supplementProbiotic

    The trial phase of this study lasted 12 weeks, and each patient will make 4 visits (week 0, week 4, week 8, week 12)

  • Dietary supplementPlacebo

    The trial phase of this study lasted 12 weeks, and each patient will make 4 visits (week 0, week 4, week 8, week 12)

06

What researchers measure

Primary outcomes

  1. Change from baseline in body weight following the intervention

    Body weight will be assessed using a calibrated digital scale under standardized conditions

    Time frame: Baseline (Week 0) and Weeks 4, 8, and 12

07

Study locations

1 site
  • The School of Food and Bioengineering, Henan University of Science and Technolog
    Luoyang, Henan 471000, China
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Apr 2, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07507929
Responsible party
Sponsor
First posted
Apr 2, 2026
Start date
Mar 20, 2026 (estimated)
Primary completion
Dec 1, 2026 (estimated)
Completion
Dec 30, 2026 (estimated)
Last update
Apr 2, 2026

Study contacts

Ying Wu, doctor
Contact
yingwu@haust.edu.cn
18639283502

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Probiotic

Start the discussion